Blood reviews · 2026
What population-based databases reveal about equity in access to hematopoietic cell transplant and cellular therapy.
СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Hong Sanghee, Espinoza-Gutarra Manuel Ricardo, Shah Rahul, Demartino Patrick, Davies Stella M, Nemecek Eneida, Howard Dianna, DeSalvo Anna M, Meyer Christa L, Majhail Navneet S, Preussler Jaime, Hall Anurekha G, Arteaga Alexandra Gomez, Auletta Jeffery J, Khera Nandita, American Society of Transplantation, Cellular Therapy (ASTCT)- National Marrow Donor Program (NMDP) ACCESS Initiative
Аннотация
BACKGROUND: Large population-based databases are increasingly used to study access to hematopoietic cell transplantation (HCT) and chimeric antigen receptor T-cell (CAR-T) therapy.
METHODS: We conducted a systematic scoping review of studies using US databases (1/2008-2/2025) to examine access to HCT or CAR-T therapy for hematologic malignancies to identify limitations and explain differences in reported disparities.
RESULTS: Thirty-five studies met inclusion criteria, and 46% used linked databases. Across data sources, older age, racial and ethnic minoritized status, lower neighborhood socioeconomic status, and non-private insurance were associated with lower likelihood of HCT and CAR-T receipt. However, disparities varied substantially by databases due to differences in eligible populations, data availability, and ability to identify treatment candidacy.
CONCLUSION: No single database adequately characterizes disparities in access to cellular therapies. Equity-focused research requires deliberate alignment of research questions with database strengths and greater investment in data standardization and inclusion of social determinants of health.
METHODS: We conducted a systematic scoping review of studies using US databases (1/2008-2/2025) to examine access to HCT or CAR-T therapy for hematologic malignancies to identify limitations and explain differences in reported disparities.
RESULTS: Thirty-five studies met inclusion criteria, and 46% used linked databases. Across data sources, older age, racial and ethnic minoritized status, lower neighborhood socioeconomic status, and non-private insurance were associated with lower likelihood of HCT and CAR-T receipt. However, disparities varied substantially by databases due to differences in eligible populations, data availability, and ability to identify treatment candidacy.
CONCLUSION: No single database adequately characterizes disparities in access to cellular therapies. Equity-focused research requires deliberate alignment of research questions with database strengths and greater investment in data standardization and inclusion of social determinants of health.